⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Farmacéuticos Rayere and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Farmacéuticos Rayere
↗Mexico City, Mexico
Farmacéuticos Rayere is a privately held Mexican pharmaceutical manufacturer and marketer founded in 1965. The company develops, manufactures, and commercializes branded generics, prescription products, and over-the-counter medicines, with particular historical emphasis on analgesic, anti-inflammatory, and respiratory products. Its commercial structure includes the Primus prescription division and products for primary-care and open-access markets. ([rayere.com.mx](https://www.rayere.com.mx/nosotros.html))
Rayere positions itself as an innovation-oriented, vertically integrated pharmaceutical company with internal R&D and manufacturing capabilities. Its website states that the R&D organization has registered six patents, two of which have become marketed products; independent patent literature shows a broader portfolio of Mexican and international patent families focused primarily on synergistic fixed-dose analgesic combinations and neuropathic-pain formulations. ([rayere.com.mx](https://www.rayere.com.mx/nosotros.html))
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Branded generics, patented fixed-dose analgesic combinations, and Mexican pharmaceutical manufacturing
SIZE & FINANCIALS
Employees:51-200
Founded:1965
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial marketed products; no publicly documented late-stage clinical development pipeline
Modalities:Small molecule, Branded generic drugs, Fixed-dose combinations, Oral tablets and capsules, Injectable formulations, Topical formulations, Syrups and oral solutions
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Siegfried Rhein, S.A. de C.V.: historical exploitation/license relationship for Rayere's diclofenac/lysine-clonixinate patented combination. ([olivares.mx](https://www.olivares.mx/wp-content/uploads/2018/09/1-17-ago.pdf?utm_source=openai)), PHARMET, S.A. de C.V.: provider of information and study services for several Rayere-sponsored pharmacokinetic and bioequivalence studies. ([siipris03.cofepris.gob.mx](https://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicosDetalle.asp?idsolicitud=3121)), Unnamed established Mexican pharmaceutical company: Rayere stated in a 2016 interview that it was licensing two patented treatments to an established Mexican company; the partner was not identified publicly. ([pharmaboardroom.com](https://pharmaboardroom.com/interviews/interview-general-directors-rayere-mexico/))
COMPETITION
Position:Niche Player
Competitors:Siegfried Rhein, Laboratorios Senosiain, Laboratorios Silanes, Laboratorios Liomont, Carnot / Productos Científicos, Laboratorios Kener, Sanfer, Psicofarma +3 more
LEADERSHIP
Key Executives:
Antonio Rosas Guinea - Industry association council representative for Farmacéuticos Rayere
Miguel Gómez - Director Médico
Alonso Marcel Hernández López - Senior pharmaceutical executive
Luz María Malo Juvera - Senior Product Manager
LINKS
Website:rayere.com.mx
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Farmacéuticos Rayere. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.